, MRA) could be used as add-on therapy Key Question 8 Initial therapy: thiazide-type diuretics, ACEIs, CCBs, beta blockers With second drug added in at a later time from list above Key Question 9 Placebo A different fourth drug (any) Key Question 10 Usual care No intervention Wait list Active intervention unrelated to blood pressure Another telemonitoring method from intervention list with a different intensity Key Question 11 Usual care No intervention Wait list Active intervention unrelated to blood pressure Another intervention from intervention list with a different intensity Key Question 12 No screening d. Outcomes Key Question 1 Critical outcomes: specificity, sensitivity, positive predictive values (PPV), negative predictive values (NPV), area under curve (AUC), etc. to diagnose and manage HTN, including white coat HTN, masked HTN, undiagnosed masked HTN Key Question 2 Critical outcomes: Reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control; adherence to therapy, percentage of patients taking medications Important outcomes: composite cardiovascular (CV) outcomes; CV and all-cause mortality; strokes; reduction in CV risks; time to blood pressure control, number of office visits to achieve control Key Question 3 Critical outcomes: Reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control Important outcomes: composite CV outcomes; CV and all-cause mortality; coronary events; strokes; safety; reduction in antihypertensive medications, number of antihypertensive medications Key Question 4 Critical outcomes: Reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control Important outcomes: composite CV outcomes; CV and all-cause mortality; coronary events; strokes; CHF; reduction in CV risks Key Questions 5 and 6 Critical outcomes: composite CV outcomes Important outcomes: CV and all-cause mortality; coronary events; strokes; CHF; renal function; safety Key Question 7 Critical outcomes: composite CV outcomes Important outcomes: CV and all-cause mortality; strokes; CHF; renal function; safety; reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control Key Question 8 Critical outcomes: reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control Important outcomes: composite CV outcomes; safety; time to blood pressure control, number of office visits to achieve control; adherence to therapy, percentage of patients taking medications Key Question 9 Critical outcomes: safety; reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control Important outcomes: composite CV outcomes; strokes; CHF; renal function Key Questions 10 and 11 Critical outcomes: Reduction in blood pressure, change in blood pressure from baseline, achievement of lower blood pressure goals, HTN control; adherence to therapy, percentage of patients taking medications Important outcomes: patient quality of life; safety, AEs/adverse events Key Question 12 Critical outcomes: composite outcomes Important outcomes: CV and all-cause mortality; strokes, renal function; reduction in CV risk; diagnosis of masked HTN; dosing and drug selection decisions for antihypertensive drugs B. 